Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
Clinical trial NCT07328490 · WITHDRAWN
Trial details
- NCT number
- NCT07328490
- Sponsor
- National Cancer Institute (NCI)
- Status
- WITHDRAWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-25
- Primary completion
- 2026-04-25
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.